Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

A dynamic comprehensive geriatric assessment demonstrates improvement in patient fitness after induction and predicts survival and treatment tolerability among older adults with newly diagnosed acute myeloid leukemia

Blood (2025) 146 (Supplement 1): 5153.

https://doi.org/10.1182/blood-2025-5153

Published: 2025

Journal Articles

The impact of environmental air exposues on disease characteristics and outcomes in a cohort of patients with myelofibrosis

Blood (2025) 146 (Supplement 1): 2838.

https://doi.org/10.1182/blood-2025-2838

Published: 2025

Journal Articles

Trial in progress – a phase 1b trial of ivosidenib combined with ruxolitinib in IDH1-mutated advanced myeloproliferative neoplasms

Anand Patel, Theodore Karrison, Emily Dworkin, Rafael Madero-Marroquin, Austin Wesevich, Gregory Roloff, Caner Saygin, Mariam Nawas, Michael Drazer, Adam Duvall, Satyajit Kosuri, Michael Thirman, Wendy Stock, Richard Larson, Olatoyosi Odenike

Blood (2025) 146 (Supplement 1): 5608.

https://doi.org/10.1182/blood-2025-5608

Published: 2025

Journal Articles

Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes

Blood (2025) 146 (Supplement 1): 239.

https://doi.org/10.1182/blood-2025-239

Published: 2025

Journal Articles

County-level analysis reveals two high-incidence regions and potential environmental contributors to myeloid malignancies in Colorado

Jason Gilbert, Diana Abbott, Elizabeth Molina Kuna, Marcelo Perraillon, Anand Patel, Daniel Pollyea

Blood (2025) 146 (Supplement 1): 2853.

https://doi.org/10.1182/blood-2025-2853

Published: 2025

Journal Articles

Choice of hypomethylating agent for newly diagnosed TP53-mutant Acute Myeloid Leukemia: A command registry study

Blood (2025) 146 (Supplement 1): 874.

https://doi.org/10.1182/blood-2025-874

Published: 2025

Journal Articles

Decreased serum total cholesterol is associated with worse outcomes among patients with myeloproliferative neoplasms

Orly Leiva, Steven Soo, Olivia Liu, Victor You, Andrew Palmer, Justin Kahla, Yasmeen Murtaza, Olatoyosi Odenike, Anand Patel, Jeanne DeCara, Michelle Lee, Chi-Joan How, Max Petersen, Patrycja Dubielecka, Gabriela Hobbs

Blood (2025) 146 (Supplement 1): 2020.

https://doi.org/10.1182/blood-2025-2020

Published: 2025

Journal Articles

Hairy cell leukemia treatment strategies: A real-world multicenter experience

James Fradin, Lisa Rein, Aniko Szabo, Karen-Sue Carlson, Talha Badar, Troy Holden, Shiv Shah, Annie Im, Anand Patel, Ehab Atallah

Blood (2025) 146 (Supplement 1): 1802.

https://doi.org/10.1182/blood-2025-1802

Published: 2025

Journal Articles

An independent, multi-center analysis of the post-approval utilization and efficacy of pacritinib and momelotinib in patients with myelofibrosis

Andrew Kuykendall, Douglas Tremblay, Anthony Hunter, Pankit Vachhani, Alexander Coltoff, Anand Patel, Ashwin Kishtagari, Jeremy DiGennaro, Dahniel Sastow, Sandra Jones, Jay Jarodiya, Georgio Medawar, Shiv Shah, Naimisha Marneni, Megan Metzger, Ashley Yu, Rami Komrokji, John Mascarenhas

Blood (2025) 146 (Supplement 1): 5600.

https://doi.org/10.1182/blood-2025-5600

Published: 2025

Journal Articles

Trial in progress - a randomized study of ASTX727 with or without Iadademstat in accelerated/blast-phase myeloproliferative neoplasms

Anand Patel, Michael Drazer, Theodore Karrison, Lorraine Pelosof, Steven Gore, Richard Little, Alexey Danilov, Olatoyosi Odenike

Blood (2025) 146 (Supplement 1): 3827.

https://doi.org/10.1182/blood-2025-3827

Published: 2025

Journal Articles

Ruxolitinib and cardiovascular outcomes among patients with myelofibrosis

Orly Leiva, Steven Soo, Olivia Liu, Victor You, Andrew Palmer, Justin Kahla, Yasmeen Murtaza, Olatoyosi Odenike, Anand Patel, Jeanne DeCara, Michelle Lee, Chi-Joan How, Gabriela Hobbs

Blood (2025) 146 (Supplement 1): 3796.

https://doi.org/10.1182/blood-2025-3796

Published: 2025

Journal Articles

Spiritual wellness and quality-of-life in adult patients with newly diagnosed acute leukemia receiving initial therapy: Patient-reported outcomes (PROs) from a prospective observational study

Hannah Johnston, Abigail Sneider, Tuula Pera, Rafael Madero-Marroquin, Austin Wesevich, Gregory Roloff, Mariam Nawas, Anand Patel, Michael Drazer, Adam Duvall, Satyajit Kosuri, Michael Thirman, Olatoyosi Odenike, Richard Larson, Caner Saygin, Wendy Stock, Christopher Daugherty

Blood (2025) 146 (Supplement 1): 6382.

https://doi.org/10.1182/blood-2025-6382

Published: 2025

Journal Articles

Real-world practice patterns of IDH inhibitors and outcomes of on-label IDH inhibitor use for Acute Myeloid Leukemia in the United States

Blood (2025) 146 (Supplement 1): 1614.

https://doi.org/10.1182/blood-2025-1614

Published: 2025

Journal Articles

Revumenib in combination with intensive induction and consolidation for newly diagnosed patients with NPM1-mutated or KMT2A-rearranged Acute Myeloid Leukemia: Preliminary results from the Phase 1b etctn 10596 study

Alice Mims, Lai Wei, Eric McLaughlin, Jayanshu Jain, Joshua Zeidner, Olatoyosi Odenike, Sangeetha Venugopal, James Blachly, Vu Duong, Anand Patel, Eric Eisenmann, Shelley Orwick, Daelynn Buelow, Gregory Behbehani, Richard Little, Steven Gore, Sharyn Baker

Blood (2025) 146 (Supplement 1): 5206.

https://doi.org/10.1182/blood-2025-5206

Published: 2025

Journal Articles

Clinical and molecular characteristics of Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia with central nervous system relapse versus systemic relapse: Results from consortium on myeloid malignancies and neoplastic diseases (COMMAND)

Blood (2025) 146 (Supplement 1): 3320.

https://doi.org/10.1182/blood-2025-3320

Published: 2025

Journal Articles

Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study

Blood (2025) 146 (Supplement 1): 453.

https://doi.org/10.1182/blood-2025-453

Published: 2025

Journal Articles

Primary efficacy analysis of phase II study investigating tyrosine kinase inhibitor (TKI) and inotuzumab ozogamicin-based therapy for newly diagnosed Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

Blood (2025) 146 (Supplement 1): 441.

https://doi.org/10.1182/blood-2025-441

Published: 2025

Journal Articles

Outcomes following lower-intensity therapy with venetoclax in patients with NPM1-mutated Acute Myeloid Leukemia are highly dependent upon co-occurring mutations

Blood (2025) 146 (Supplement 1): 5278.

https://doi.org/10.1182/blood-2025-5278

Published: 2025

Journal Articles

Trial in progress: A Phase I/II study to investigate the combination of LP-118, ponatinib, vincristine and dexamethasone (LPVd regimen) in relapsed/refractory T-ALL/lbl

Blood (2025) 146 (Supplement 1): 5136.

https://doi.org/10.1182/blood-2025-5136

Published: 2025

Journal Articles

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

Blood (2025) 146 (Supplement 1): 2018.

https://doi.org/10.1182/blood-2025-2018

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A dynamic comprehensive geriatric assessment demonstrates improvement in patient fitness after induction and predicts survival and treatment tolerability among older adults with newly diagnosed acute myeloid leukemia

The impact of environmental air exposues on disease characteristics and outcomes in a cohort of patients with myelofibrosis

Trial in progress – a phase 1b trial of ivosidenib combined with ruxolitinib in IDH1-mutated advanced myeloproliferative neoplasms

Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes

County-level analysis reveals two high-incidence regions and potential environmental contributors to myeloid malignancies in Colorado

Choice of hypomethylating agent for newly diagnosed TP53-mutant Acute Myeloid Leukemia: A command registry study

Decreased serum total cholesterol is associated with worse outcomes among patients with myeloproliferative neoplasms

Hairy cell leukemia treatment strategies: A real-world multicenter experience

An independent, multi-center analysis of the post-approval utilization and efficacy of pacritinib and momelotinib in patients with myelofibrosis

Trial in progress - a randomized study of ASTX727 with or without Iadademstat in accelerated/blast-phase myeloproliferative neoplasms

Ruxolitinib and cardiovascular outcomes among patients with myelofibrosis

Spiritual wellness and quality-of-life in adult patients with newly diagnosed acute leukemia receiving initial therapy: Patient-reported outcomes (PROs) from a prospective observational study

Real-world practice patterns of IDH inhibitors and outcomes of on-label IDH inhibitor use for Acute Myeloid Leukemia in the United States

Revumenib in combination with intensive induction and consolidation for newly diagnosed patients with NPM1-mutated or KMT2A-rearranged Acute Myeloid Leukemia: Preliminary results from the Phase 1b etctn 10596 study

Clinical and molecular characteristics of Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia with central nervous system relapse versus systemic relapse: Results from consortium on myeloid malignancies and neoplastic diseases (COMMAND)

Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study

Primary efficacy analysis of phase II study investigating tyrosine kinase inhibitor (TKI) and inotuzumab ozogamicin-based therapy for newly diagnosed Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

Outcomes following lower-intensity therapy with venetoclax in patients with NPM1-mutated Acute Myeloid Leukemia are highly dependent upon co-occurring mutations

Trial in progress: A Phase I/II study to investigate the combination of LP-118, ponatinib, vincristine and dexamethasone (LPVd regimen) in relapsed/refractory T-ALL/lbl

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only